Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A novel vaccine that targets tumor vessels as an efficient tool in tumor therapy

A vaccine, a form of technology, applied in a novel field that can solve problems such as the impossibility of obtaining effective tumor vaccines

Inactive Publication Date: 2012-11-21
THERAVAC PHARMA
View PDF8 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This has also led almost all research groups in the field of tumor biology to conclude that it is impossible to obtain an effective tumor vaccine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A novel vaccine that targets tumor vessels as an efficient tool in tumor therapy
  • A novel vaccine that targets tumor vessels as an efficient tool in tumor therapy
  • A novel vaccine that targets tumor vessels as an efficient tool in tumor therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0026] To test the efficacy of the present invention, a fusion protein between the 91 amino acid long extracellular domain B (EDB) of human and mouse fibronectin and the bacterial antigen E. coli thioredoxin with a size of approximately 10 kD was used as a vaccine Antigens to study their effects in animal models. The EDB domain is extremely highly conserved and nearly identical in all placental mammals studied. This fusion protein is produced almost homogeneously in prokaryotic hosts ( figure 2 ). Thioredoxin-EDB-fusion protein was then injected into mice together with adjuvant. After 3 weeks, the mice received a booster dose of the vaccine, and after 5 weeks of treatment, the sera from these animals were tested for the amount of anti-EDB antibodies produced. as from image 3 As seen in , all animals showed high titers of anti-EDB antibodies, whereas all controls were negative. This shows that the vaccine has the ability to induce a large amount of anti-EDB antibody prod...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a composition for the treatment of various cancers. The composition is a vaccine containing sequences of EDB, EDA, annexin A1, endosialin, C domain of tenascin C or magic roundabout (MR) or fragments thereof as single or in a combination coupled to one or several heterologous foreign carrier molecules. The vaccine will produce antibodies that are directed against self proteins which are preferentially expressed in and around tumor vessels. The vaccine is preferably administrated together with an adjuvant.

Description

technical field [0001] The present invention relates to a novel approach designed to stimulate the immune system to produce antibodies that target tumor blood vessels almost exclusively. These antibodies against self-proteins that are preferentially expressed in and around tumor blood vessels lead to an immune attack on tumor blood vessels that induces a marked slowing of tumor growth. Although the present invention relates generally to vaccines for use in mammals, preferred embodiments relate to vaccines for use in humans, dogs, cats or horses, and the present invention will generally refer to such vaccines for use in humans, canines, felines Vaccines for use in animals and equines are described. Background technique [0002] Angiogenesis - the formation of new capillaries - is critical during development and in physiological conditions that require angiogenesis, such as wound healing and the menstrual cycle. However, in healthy males, angiogenesis is rare and the endothe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/385A61K38/17A61P35/00A61K39/00
CPCA61K39/0011C07K2319/40C07K14/4721C07K14/47C07K14/7056A61K2039/6068C07K14/78C07K17/00C07K14/705A61P35/00A61K2039/80A61K38/17A61K39/385
Inventor A-K·奥尔森L·赫尔曼
Owner THERAVAC PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com